• Revenue increased 40% to $81.4 million in FY25
• EBITDA grew 62% to $13.0 million, with margins improving to 16.0%
• Net Profit Before Tax reached $8.1 million, up from $5.7 million in FY24

Austco Healthcare Limited (Austco), a global leader in clinical communications solutions, has announced its financial results for the year ended 30 June 2025. The company reported record revenues of $81.4 million, an increase of 40% compared to the previous financial year. This strong performance was driven by both organic growth in existing operations and additional revenue from acquisitions. All three acquisitions completed to date have been established Austco-authorised resellers. Under consolidation accounting rules, sales to these businesses, which were previously recorded as organic revenue, are now eliminated from reported results. As a result, the reported revenue figures may not fully reflect the underlying growth of Austco's organic business. Software and SMA (Software Maintenance Agreements) revenues increased by 3% to $9.6 million in FY25. Gross margins remained healthy at 52.0%, although they eased slightly from 52.7% in the prior year, partly due to the impact of US tariffs and the integration of the new acquisitions. Overhead expenses increased by $6.9 million to $32.6 million, with a significant portion of this increase relating to the three acquired businesses. EBITDA grew by 62% to $13.0 million, reflecting the company's strong operating leverage, with EBITDA margins improving from 13.8% in FY24 to 16.0% in FY25. Net Profit Before Tax reached $8.1 million, up from $5.7 million in the previous year, while Net Profit After Tax was $5.9 million, compared to a record $7.1 million in FY24. The decline in NPAT was due to the impact of a $1.4 million tax credit booked in FY24 and a $2.2 million one-off contingent consideration expense in FY25. Austco's Unfilled Contracted Revenue (UCR) book now stands at $53.8 million as of 13 August 2025, reflecting the company's continued growth and strong sales pipeline. The company invested $4.8 million in research and development during the reporting period, of which $2.0 million was capitalized. Cash on hand at the end of the financial year was $14.5 million, up from $13.6 million a year earlier, allowing the company to fund future growth initiatives without the need for debt or capital raising.

Austco expects to deliver continued revenue growth, improved profitability, and increasing EBITDA margins in the 2026 financial year.

Austco is well-positioned to capitalize on the growing demand for its innovative clinical communications solutions, with a strong sales pipeline and a focus on operational improvements and supply chain efficiencies to drive further margin expansion.